Chen Jiali, Chen Shi, He Jing
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):116-118. Epub 2017 Sep 21.
We describe a young female patient who had refractory intestinal Behçet's disease that responded to tocilizumab, a humanised anti-interleukin-6 receptor antibody. The patient had suffered from long disease activity courses and was treated with multiple medications, and the disease became refractory when immunosuppressants (e.g., thalidomide, sulfasalazine and azathioprine) were limited for poor remission, methylprednisolone pulse therapy, cyclophosphamide, and biological agents (e.g., adalimumab or infliximab) were restricted due to side effects after administration. Therefore, tocilizumab was considered as a therapeutic option and the symptoms resolved during 9 months of administration. Tocilizumab may be a good choice for intestinal Behçet's disease refractory to conventional treatment.
我们描述了一名年轻女性患者，她患有难治性肠道白塞病，对人源化抗白细胞介素-6受体抗体托珠单抗有反应。该患者病程较长且疾病活动频繁，曾接受多种药物治疗，当免疫抑制剂（如沙利度胺、柳氮磺胺吡啶和硫唑嘌呤）因缓解不佳而受限，甲基强的松龙冲击疗法、环磷酰胺以及生物制剂（如阿达木单抗或英夫利昔单抗）因用药后出现副作用而受到限制时，疾病变得难治。因此，托珠单抗被视为一种治疗选择，在给药9个月期间症状得到缓解。对于传统治疗难治的肠道白塞病，托珠单抗可能是一个不错的选择。
